Lazabemide

Lazabemide
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide;
CAS Number	103878-84-8;
PubChem CID	71307;
IUPHAR/BPS	6640;
ChemSpider	64426;
UNII	420HD787N9;
KEGG	D04681;
CompTox Dashboard (EPA)	DTXSID2048294 ;
Chemical and physical data
Formula	C8H10ClN3O
Molar mass	199.64 g·mol−1

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.^[1]

References

^ Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings". In Tipton KF, Youdim MB, Barwell CJ, Callingham BA, Lyles GA (eds.). Amine Oxidases: Function and Dysfunction. Proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22–25, 1992. Journal of Neural Transmission. Supplementum. Vol. 41. pp. 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN 978-3-211-82521-1. PMID 7931245.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid7931245-1] Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings". In Tipton KF, Youdim MB, Barwell CJ, Callingham BA, Lyles GA (eds.). Amine Oxidases: Function and Dysfunction. Proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22–25, 1992. Journal of Neural Transmission. Supplementum. Vol. 41. pp. 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN 978-3-211-82521-1. PMID 7931245.

[1]